Loading
Latest filing published 16 Jul 2026 for Cardiff Oncology, Inc., €44k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Mani Mohindru is a declared insider at 2 companies; the most frequent names are Tvardi Therapeutics, Inc. and Cardiff Oncology, Inc. The record holds 16 filings, for trades running from 17 October 2018 to 14 July 2026.
On the open market, the record shows 2 purchases worth €70k and 7 sales worth €1.8M. Netting one side against the other leaves €1.7M of net selling. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 3 share grants and 4 option exercises. Since January 2026: 2 purchases and no sales on the market.
The newest entry dates from 16 July 2026: an open-market purchase of €44k, in Cardiff Oncology, Inc. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations